How much is Acrivon Therapeutics worth in 2026?

Acrivon Therapeutics has a current valuation of N/A based on their PIPE round and secondary market data.

How much funding has Acrivon Therapeutics raised?

Acrivon Therapeutics has raised N/A in total funding across 2 funding rounds.

Acrivon Therapeutics

Drug Discovery

Acrivon Therapeutics valuation and funding history | Last updated: April 11, 2024 | 2 funding rounds

Current Valuation

N/A

As of April 11, 2024

Total Funding Raised

N/A

Across 2 rounds

Last Round

PIPE

$130.0M

Last Funding

Apr 2024

Funding date

Capital Efficiency

N/A

Valuation / Funding

Funding History & Valuation Timeline

Complete history of all funding rounds and valuation milestones

Date	Round	Amount	Post-Valuation	Growth
April 11, 2024	PIPE	$130.0M	N/A	-
November 11, 2021	Early Stage VC (Series B)	$100.0M	N/A	-

Valuation Analysis

Current Valuation Metrics

Acrivon Therapeutics is currently valued at N/A as of April 11, 2024.

Track Acrivon Therapeutics Valuation Updates

Get notified when Acrivon Therapeutics raises new funding or valuation changes

Explore More Data

Detailed analysis for Acrivon Therapeutics

Secondary Market Price

Real-time pricing data and trends

Valuation Tracker

Historical valuation changes

Funding History

Complete funding round timeline

Secondary Price History

Historical transaction data

All Investors

Complete list of all investors

View 5 companies free

Create a free account to unlock Acrivon Therapeutics's valuation history, funding rounds, and growth metrics.

No credit card required

What is Acrivon Therapeutics Worth in 2026?

Acrivon Therapeutics is a leading private company in the Drug Discovery sector. Track Acrivon Therapeutics's valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.

How Acrivon Therapeutics Valuation is Determined

Private company valuations like Acrivon Therapeutics's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.